Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval of its ANDA for Daptomycin for injection (500mg vial), from the U.S Food and Drug Administration (USFDA). This product is indicated for use in the treatment of complicated skin and skin structure infections (cSSSI).
It is also used to treat Staphylococcus aureus infections in the bloodstream (bacteremia), including right-sided infective endocarditis in adult patients. The approval further adds to Biocon’s portfolio of complex drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
